MCL1 and acute myeloid leukemia: A dual AXL and MER Tyrosine Kinase (MERTK) inhibitor ONO-7475 has strong antileukemic effects in FLT3-ITD AML cells, by suppressing ERK1/2 phosphorylation and MCL-1 expression.